Relative Strength Chart Alnylam Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 17/04/2026 BST			5-day change	1st Jan Change
309.66 ^USD	-3.27%		-3.87%	-22.13%

04-06	BioCryst Pharmaceuticals, Inc. Appoints Sandeep M. Menon As Chief Research And Development Officer	CI
03-30	Alnylam Pharmaceuticals Announces New Data Supporting Benefits of Vutrisiran in Attr-Cm and Potential of Zilebesiran for Hypertension Management	CI

End-of-day quotes

		Sector	Change	5d. change	Varia. Jan 1.	1-year change	5-years change	Capi.	ST	MT	LT
	ALNYLAM PHARMACEUTICALS, INC.	Other Pharmaceuticals	-3.27%	-3.87%	-22.13%	+32.02%	+125.37%	41.07B